Sponsor Overview
Explore verified public information about Biohaven Pharmaceuticals's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Biohaven may consider Expanded Access requests if the following factors are met: - The investigational drug is being studied under an appropriate regulatory authorization - The person has a serious or immediately life-threatening illness and there is no satisfactory alternative therapy - The person is unable to participate in a clinical trial due to eligibility criteria or other reasons - There is preliminary clinical evidence of effectiveness and acceptable safety of the investigational treatment for that condition - The potential benefit of the investigational medicine is greater than the potential risk - There is an adequate supply of the investigational medicine to support the clinical trials and the expanded access request, until and if the drug becomes commercially available”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: SCA, Spinocerebellar Ataxias
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 2 supporting sources.
Conditions: Multiple System Atrophy (MSA)
Conditions: Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Requests for Early Access must be made by a physician on behalf of their patient. A licensed physician overseeing the patient’s care, who is able to comply with Biohaven’s requirements, may contact Biohaven at BHV0223.ExpandedAccess@earlyaccesscare.com or call toll-free in the United States at 1-888-315-5797 (Option 6).
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.